Abstract: Separation processes using forward osmosis are disclosed generally involving the extraction of a solvent from a first solution to concentrate a solute therein by using a second concentrated solution to draw the solvent from the first solution across a semi-permeable membrane. One or both of the solute and solvent may be a desired product. By manipulating the equilibrium of the soluble and insoluble species of solute within the second solution, a saturated second solution can be used to generate osmotic pressure on the first solution. The various species of solute within the second solution can be recovered and recycled through the process to affect the changes in equilibrium and eliminate waste products. Enhanced efficiency may result from using low grade waste heat from industrial or commercial sources.

Abstract: The invention relates generally to genetically modified non-human animals expressing human polypeptides and their methods of use.

Abstract: Polymeric nanoparticles encapsulating inhibitory ribonucleic acids (RNAs) and methods of their manufacture and use are provided. Advantageous properties of the nanoparticles include: 1) high encapsulation efficiency of inhibitory RNAs into the nano articles, 2) small size of the nanoparticles that increases cell internalization, and 3) sustained release of encapsulated inhibitory RNAs by the nanoparticles that allows for administration of an effective amount of inhibitory RNAs to cells or tissues over extended periods of time. Encapsulation efficiency of inhibitory RNAs into the nanoparticles is greatly increased by complexing the inhibitory RNAs to polycations prior to encapsulation. Methods of using the polymeric nanoparticles for treating or inhibiting diseases or disorders are provided.

Abstract: An endovascular graft is provided that includes a stent structure adapted to move between a collapsed and a deployed configuration. An endovascular graft material is mounted with respect to the stent structure. At least one lumen- or chute-forming structure is associated with the stent structure internal to the endovascular graft material. The at least one lumen- or chute-forming structure is adapted to move between a first position and a second position, wherein the at least one lumen- or chute-forming structure is rolled within itself in the first position, and wherein the at least one lumen- or chute-forming structure moves from the first position to the second position by unrolling. When in the second position, the at least one lumen- or chute-forming structure defines a passage having a greater cross-sectional area as compared to the first position. Stent-graft deployment to one or more branch arteries/vessels may be accomplished through the at least one lumen- or chute-forming structure.

Abstract: An environmentally sensitive membrane binding polypeptide, pH (low)-sensitive membrane peptide (pHLIP) has improved insertion kinetics balanced with solubility to selectively target acidic tissues.

Abstract: Exemplary embodiments of the present disclosure are directed to three-dimensional (3D) Ferroelectric-gated FET (FeFET) structures that can be used to implement circuitry include memory cells, memory arrays, and/or other logic-based circuitry. For example, in exemplary embodiments, 3D FeFET AND memory arrays with vertical and horizontal channel structures are provided.

Abstract: The present invention provides a peptide having an amino acid sequence as set forth in SEQ ID NOs: 1 through 95 and any combination thereof. The peptide or combination of peptides possess OCT4 specific inducibility. The peptide or combination of peptides can further be used as a vaccine.

Abstract: One aspect of the invention provides a method including: obtaining neural activity data for a first subject and a second subject during verbal interaction between the first subject and the second subject; and calculating coherence between the neural activity data for the first subject and the neural activity data for the second subject. Another aspect of the invention provides a non-transitory, tangible computer-readable medium comprising computer-readable program instructions for implementing the one or more of the methods described herein.

Abstract: Antimicrobial compositions including a cell penetrating peptide (CPP) having the amino acid sequence Tyr-Ala-Arg-Val-Arg-Arg-Arg-Gly-Pro-Arg-Gly-Tyr-Ala-Arg-Val-Arg-Arg-Arg-Gly-Pro-Arg-Arg (SEQ ID NO:1) or variant thereof are disclosed. The CPP, which itself has antimicrobial properties, can be advantageously combined with or conjugated to a cargo to increase the delivery, efficacy, or combinations thereof, of the cargo into cells. In preferred embodiments, the CPP is combined with or conjugated to a functional nucleic acid, such as an external guide sequence (EGS) which can target and reduce expression of essential microbial genes or genes than impart resistance to antimicrobial drugs. Methods of using the compositions alone or in combination with traditional antimicrobial drugs to treat infections are also disclosed.

Abstract: Solution-phase (e.g., homogeneous) or surface-immobilized (e.g., heterogeneous) electrode-driven oxidation catalysts based on iridium coordination compounds which self-assemble upon chemical or electrochemical oxidation of suitable precursors and methods of making and using thereof are. Iridium species such as {[Ir(LX)x(H2O)y(?-O)]zm+}n wherein x, y, m are integers from 0-4, z and n from 1-4 and LX is an oxidation-resistant chelate ligand or ligands, such as such as 2(2-pyridyl)-2-propanolate, form upon oxidation of various molecular iridium complexes, for instance [Cp*Ir(LX)OH] or [(cod)Ir(LX)] (Cp*=pentamethylcyclopentadienyl, cod=cis-cis,1,5-cyclooctadiene) when exposed to oxidative conditions, such as sodium periodate (NaIO4) in aqueous solution at ambient conditions.

Abstract: Methods for treating or preventing neointima stenosis are disclosed. The methods generally involve the use of a TGF? inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof, to inhibit endothelial-to-mesenchymal transition (Endo-MT) of vascular endothelial cells into smooth muscle cells (SMC) at sites of endothelial damage. The disclosed methods can therefore be used to prevent or inhibit neointimal stenosis or restenosis, e.g., after angioplasty, vascular graft, or stent. Also disclosed are methods for increasing the patency of biodegradable, synthetic vascular grafts using a composition that inhibits Endo-MT. A cell-free tissue engineered vascular graft (TEVG) produced by this method is also disclosed.

Abstract: Multivalent CT or MR contrast agents and methods of making and using thereof are described herein. The agents contain a moiety, such as a polymer, that provides multivalent attachment of CT or MR contrast agents. Examples include, but are not limited to, multivalent linear polymers, branched polymers, or hyperbranched polymers, such as dendrimers, and combinations thereof. The dendrimer is functionalized with one or more high Z-elements, such as iodine. The high Z-elements can be covalently or non-covalently bound to the dendrimer. The dendrimers are confined in order to enhance CT contrast. In some embodiments, the moiety is confined by encapsulating the dendrimers in a material to form particles, such as nanoparticles. In other embodiments, the dendrimer is confined by conjugating the moiety to a material, such as a polymer, which forms a gel upon contact with bodily fluids.

Abstract: A method of joining a bulk metallic glass to a second similar or dissimilar material in an air environment. The method includes the steps of: a) removing an oxide layer on at least a portion of a surface of a first bulk metallic glass during thermoplastic forming of the first bulk metallic glass in a supercooled liquid region, wherein the removing of the oxide layer on the at least the portion of the surface creates a fresh surface that is at least substantially free of oxides and/or contaminants; and b) joining the fresh surface of the first bulk metallic glass to a second material.

Abstract: The present invention includes systems and methods of using real-time neurofeedback to improve the correspondence between first-person experience and specific brain activation patterns in a manner that minimally affects the experience itself. The present invention provides meditators the ability to enhance their control over their own brain activity, such as posterior cingulate cortex (PCC) activation. The present invention also provides methods for treating a disease or disorder of a subject by measuring the subject's brain activity via fMRI, presenting a representation of the measured brain activity to the subject, and instructing the subject to reduce the represented brain activity by altering their meditative state. The present invention also provides a system and method of using fMRI neurofeedback to directly correlate subjective experience with neural activation.

Abstract: Techniques for processing imaging data contaminated by sensor-dependent noise. An imaging method is described. In the imaging method, imaging data corresponding to an imaged region and acquired by at least first and second sensor elements is obtained. A parameterized model is fitted to the imaging data. The parameterized model includes a first sensor-dependent model of noise generated by the first sensor element in a first portion of the imaging data acquired by the first sensor element, and a second sensor-dependent model of noise generated by a second sensor element in a second portion of the imaging data acquired by the second sensor element. The first sensor-dependent noise model differs, at least in part, from the second sensor-dependent noise model.

Abstract: Provided are bifunctional small molecules of Formula (I): or pharmaceutically acceptable salts thereof, wherein M represents a small organic molecule which binds, covalently or non-covalently, a kinase, such as Her3 protein kinase; L1 represents a linker; and RH represents a hydrophobic group. An example of a compound of Formula (I) is a compound of Formula (II): Also provided are pharmaceutical compositions comprising a compound of Formula (I) or (II) and methods of using such compounds for treating proliferative diseases.

Abstract: The present application relates to compositions comprising and methods of using a liposome comprising a pHLIP polypeptide, wherein a lipid bilayer of the liposome is substantially free of the pHLIP polypeptide.

Abstract: Disclosed are compositions and methods for antimicrobial use. The compositions contain a small antimicrobial agent and a permeabilizing agent. The antimicrobial compositions can be antifungal or antibacterial compositions.

Abstract: The present invention includes compositions and methods for treating disease and disorders associated with pathological calcification or pathological ossification by modulating the level or activity of NPP1 or a mutant thereof, or a mutant NPP4 modified to exhibit ATP hydrolase activity similar to the hydrolase activity of NPP1.

Abstract: Provided herein are compositions, methods and uses involving antibodies that bind to ErbB, a receptor tyrosine kinase, and modulate the activity of ErbB. Also provided are uses and methods for treating disorders, such as cancer, by administering to subject an antibody that binds to ErbB.